Literature DB >> 20419498

Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1.

Lei Zhang1, Huawei Zhu, Qiang Wang, Hao Fang, Wenfang Xu, Minyong Li.   

Abstract

In order to develop promising cyclin dependent kinase 1 inhibitors, homology modeling, docking and molecular dynamic simulation techniques were applied to get insight into the functional and structural properties of cyclin dependent kinase 1 (CDK1). Since there is no reported CDK1 crystal structural data, the three dimensional structure of CDK1 was constructed based on homology modeling. An extensive dynamic simulation was also performed on a Flavopiridol-CDK1 complex for probing the binding pattern of Flavopiridol in the active site of CDK1. The binding modes of other inhibitors to CDK1 were also proposed by molecular docking. The structural requirement for developing more potent CDK1 inhibitors was obtained by the above-mentioned molecular simulations and pharmacophore modeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419498     DOI: 10.1007/s00894-010-0710-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  31 in total

1.  Secondary structure-based profiles: use of structure-conserving scoring tables in searching protein sequence databases for structural similarities.

Authors:  R Lüthy; A D McLachlan; D Eisenberg
Journal:  Proteins       Date:  1991

Review 2.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

Review 3.  Protein engineering and design.

Authors:  T L Blundell; G Elliott; S P Gardner; T Hubbard; S Islam; M Johnson; D Mantafounis; P Murray-Rust; J Overington; J E Pitts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1989-08-31       Impact factor: 6.237

Review 4.  Cyclin dependent kinase regulation.

Authors:  E Lees
Journal:  Curr Opin Cell Biol       Date:  1995-12       Impact factor: 8.382

5.  Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities.

Authors:  Nathalie Villerbu; Anne-Marie Gaben; Gérard Redeuilh; Jan Mester
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

6.  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.

Authors:  Wanda DePinto; Xin-Jie Chu; Xuefeng Yin; Melissa Smith; Kathryn Packman; Petra Goelzer; Allen Lovey; Yingsi Chen; Hong Qian; Rachid Hamid; Qing Xiang; Christian Tovar; Roger Blain; Tom Nevins; Brian Higgins; Leopoldo Luistro; Kenneth Kolinsky; Bernardo Felix; Sazzad Hussain; David Heimbrook
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

7.  Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.

Authors:  Dana Gherardi; Vivette D'Agati; Te-Hua Tearina Chu; Anna Barnett; Athos Gianella-Borradori; Irwin H Gelman; Peter J Nelson
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

8.  The decision to enter mitosis.

Authors:  W G Dunphy
Journal:  Trends Cell Biol       Date:  1994-06       Impact factor: 20.808

9.  The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.

Authors:  Kate F Byth; Catherine Geh; Cheryl L Forder; Sandra E Oakes; Andrew P Thomas
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

10.  Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells.

Authors:  S Brüsselbach; D M Nettelbeck; H H Sedlacek; R Müller
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.